Investment Analysts’ Weekly Ratings Updates for Perspective Therapeutics (CATX)

Several brokerages have updated their recommendations and price targets on shares of Perspective Therapeutics (NYSEAMERICAN: CATX) in the last few weeks:

• 8/18/2026 – Perspective Therapeutics was given a new $11.00 price target by BMO Capital Markets. They now have an “outperform” rating on the stock.
• 8/18/2026 – Perspective Therapeutics was upgraded by BMO Capital Markets to “strong-buy”.
• 8/14/2026 – Perspective Therapeutics had its price target lowered by Bank of America Corporation from $6.00 to $5.00. They now have a “neutral” rating on the stock.
• 8/11/2026 – Perspective Therapeutics had its price target lowered by Piper Sandler from $16.00 to $14.00. They now have an “overweight” rating on the stock.
• 7/24/2026 – Perspective Therapeutics had its “buy” rating reaffirmed by BTIG Research.

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.